메뉴 건너뛰기




Volumn 39, Issue 5, 2013, Pages 507-517

The development of endocrine therapy for women with breast cancer

Author keywords

Anastrozole; Aromatase inhibitors; Breast cancer; Endocrine therapy; Exemestane; Fulvestrant; Letrozole; Luteinising hormone releasing hormone; Oestrogen receptor; Tamoxifen

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; BUSERELIN; DROLOXIFENE; EXEMESTANE; FULVESTRANT; GOSERELIN; IDOXIFENE; LETROZOLE; LEUPRORELIN; MEGESTROL ACETATE; MIPROXIFENE; RALOXIFENE; TAMOXIFEN; TOREMIFENE;

EID: 84876968058     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.07.006     Document Type: Review
Times cited : (64)

References (107)
  • 3
    • 0000524684 scopus 로고
    • On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases
    • Beatson G.T. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 1896, 2:105-107.
    • (1896) Lancet , vol.2 , pp. 105-107
    • Beatson, G.T.1
  • 4
    • 0001561849 scopus 로고
    • Inhibition of human mammary and prostatic cancers by adrenalectomy
    • Huggins C., Berganstal D.M. Inhibition of human mammary and prostatic cancers by adrenalectomy. Cancer Res 1952, 12:134-141.
    • (1952) Cancer Res , vol.12 , pp. 134-141
    • Huggins, C.1    Berganstal, D.M.2
  • 5
    • 70449140922 scopus 로고
    • Experiences with hypophysectomy in cancer of the breast
    • Olivecrona H., Luft R. Experiences with hypophysectomy in cancer of the breast. Ann R Coll Surg Eng 1957, 20:267-279.
    • (1957) Ann R Coll Surg Eng , vol.20 , pp. 267-279
    • Olivecrona, H.1    Luft, R.2
  • 6
    • 0013248993 scopus 로고
    • The use of testosterone propionate in the treatment of advanced carcinoma of the breast
    • Adair F.E., Herrmann J.B. The use of testosterone propionate in the treatment of advanced carcinoma of the breast. Ann Surg 1946, 123:1023-1035.
    • (1946) Ann Surg , vol.123 , pp. 1023-1035
    • Adair, F.E.1    Herrmann, J.B.2
  • 7
    • 84873754102 scopus 로고
    • Stilboestrol in late malignant disease of the breast
    • Rae I.P. Stilboestrol in late malignant disease of the breast. Glasgow Med J 1948, 29:248-254.
    • (1948) Glasgow Med J , vol.29 , pp. 248-254
    • Rae, I.P.1
  • 8
    • 0007831904 scopus 로고
    • Response of advanced breast cancer to the combination of the anti-metabolite methotrexate and the alkylating agent thiotepa
    • Greenspan E.M., Fieber M., Lesnick G., Edelman S. Response of advanced breast cancer to the combination of the anti-metabolite methotrexate and the alkylating agent thiotepa. J Mt Sinai Hosp 1963, 30:246-267.
    • (1963) J Mt Sinai Hosp , vol.30 , pp. 246-267
    • Greenspan, E.M.1    Fieber, M.2    Lesnick, G.3    Edelman, S.4
  • 9
    • 0017740963 scopus 로고
    • Diethylstilbestrol: recommended dosages for different categories of breast cancer patients. Report of the Cooperative Breast Cancer Group
    • Carter A.C., Sedransk N., Kelley R.M., et al. Diethylstilbestrol: recommended dosages for different categories of breast cancer patients. Report of the Cooperative Breast Cancer Group. JAMA 1977, 237:2079-2085.
    • (1977) JAMA , vol.237 , pp. 2079-2085
    • Carter, A.C.1    Sedransk, N.2    Kelley, R.M.3
  • 10
    • 75449149186 scopus 로고
    • Cancer studies. Cancer of the breast.
    • Cline J.W. Cancer studies. Cancer of the breast. Cal Med 1963, 99:393-402.
    • (1963) Cal Med , vol.99 , pp. 393-402
    • Cline, J.W.1
  • 11
    • 0015069359 scopus 로고
    • A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474
    • Cole M.P., Jones C.T., Todd I.D. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer 1971, 25:270-275.
    • (1971) Br J Cancer , vol.25 , pp. 270-275
    • Cole, M.P.1    Jones, C.T.2    Todd, I.D.3
  • 12
    • 0032569831 scopus 로고    scopus 로고
    • Tamoxifen in the treatment of breast cancer
    • Osborne C.K. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998, 339:1609-1618.
    • (1998) N Engl J Med , vol.339 , pp. 1609-1618
    • Osborne, C.K.1
  • 13
    • 77955551055 scopus 로고    scopus 로고
    • American Society of Clinical Oncology Clinical Practice Guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer
    • Burstein H.J., Prestrud A.A., Seidenfeld J., et al. American Society of Clinical Oncology Clinical Practice Guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010, 28:3784-3796.
    • (2010) J Clin Oncol , vol.28 , pp. 3784-3796
    • Burstein, H.J.1    Prestrud, A.A.2    Seidenfeld, J.3
  • 14
    • 0019382847 scopus 로고
    • Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer
    • Ingle J.N., Ahmann D.L., Green S.J., et al. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 1981, 304:16-21.
    • (1981) N Engl J Med , vol.304 , pp. 16-21
    • Ingle, J.N.1    Ahmann, D.L.2    Green, S.J.3
  • 15
    • 0019236420 scopus 로고
    • The tamoxifen trial a double-blind comparison with stilboestrol in postmenopausal women with advanced breast cancer
    • Stewart H.J., Forrest A.P., Gunn J.M. The tamoxifen trial a double-blind comparison with stilboestrol in postmenopausal women with advanced breast cancer. Eur J Cancer 1980, (Suppl 1):83-88.
    • (1980) Eur J Cancer , Issue.SUPPL. 1 , pp. 83-88
    • Stewart, H.J.1    Forrest, A.P.2    Gunn, J.M.3
  • 16
    • 0018900532 scopus 로고
    • Tamoxifen and fluoxymesterone in advanced breast cancer: a controlled clinical trial
    • Westerberg H. Tamoxifen and fluoxymesterone in advanced breast cancer: a controlled clinical trial. Cancer Treat Rep 1980, 64:117-121.
    • (1980) Cancer Treat Rep , vol.64 , pp. 117-121
    • Westerberg, H.1
  • 17
    • 0015915672 scopus 로고
    • Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels
    • Ward H.W. Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br Med J 1973, 1:13-14.
    • (1973) Br Med J , vol.1 , pp. 13-14
    • Ward, H.W.1
  • 18
    • 0019167247 scopus 로고
    • Estrogen and progesterone receptors in the prediction of response of breast cancer to endocrine therapy
    • Manni A., Arafah B., Pearson O.H. Estrogen and progesterone receptors in the prediction of response of breast cancer to endocrine therapy. Cancer 1980, 46(Suppl 12):2838-2841.
    • (1980) Cancer , vol.46 , Issue.SUPPL. 12 , pp. 2838-2841
    • Manni, A.1    Arafah, B.2    Pearson, O.H.3
  • 19
    • 0035755679 scopus 로고    scopus 로고
    • Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer
    • Fisher B., Jeong J.H., Dignam J., et al. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. J Natl Cancer Inst Monogr 2001, 62-66.
    • (2001) J Natl Cancer Inst Monogr , pp. 62-66
    • Fisher, B.1    Jeong, J.H.2    Dignam, J.3
  • 20
    • 0021918182 scopus 로고
    • Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years.
    • The Nolvadex Adjuvant Trial Organisation
    • Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years. Lancet 1985, 325:836-840. The Nolvadex Adjuvant Trial Organisation.
    • (1985) Lancet , vol.325 , pp. 836-840
  • 21
    • 0024506261 scopus 로고
    • A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors
    • Fisher B., Costantino J., Redmond C., et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989, 320:479-484.
    • (1989) N Engl J Med , vol.320 , pp. 479-484
    • Fisher, B.1    Costantino, J.2    Redmond, C.3
  • 22
    • 0032427758 scopus 로고    scopus 로고
    • Early stopping of a clinical trial when there is no evidence of no treatment benefit: protocol B-14 of the National Surgical Adjuvant Breast and Bowel Project
    • Dignam J.J., Bryant J., Wieand H.S., Fisher B., Wolmark B. Early stopping of a clinical trial when there is no evidence of no treatment benefit: protocol B-14 of the National Surgical Adjuvant Breast and Bowel Project. Control Clin Trials 1998, 19:575-588.
    • (1998) Control Clin Trials , vol.19 , pp. 575-588
    • Dignam, J.J.1    Bryant, J.2    Wieand, H.S.3    Fisher, B.4    Wolmark, B.5
  • 23
    • 0035795683 scopus 로고    scopus 로고
    • Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the national surgical adjuvant breast and bowel project B-14 randomized trial
    • Fisher B., Dignam J., Bryant J., Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the national surgical adjuvant breast and bowel project B-14 randomized trial. J Natl Cancer Inst 2001, 93:684-690.
    • (2001) J Natl Cancer Inst , vol.93 , pp. 684-690
    • Fisher, B.1    Dignam, J.2    Bryant, J.3    Wolmark, N.4
  • 24
    • 0026477124 scopus 로고
    • The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. Scottish Cancer Trials Breast Group
    • Stewart H.J. The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. Scottish Cancer Trials Breast Group. J Natl Cancer Inst Monogr 1992, 117-120.
    • (1992) J Natl Cancer Inst Monogr , pp. 117-120
    • Stewart, H.J.1
  • 25
    • 0035925617 scopus 로고    scopus 로고
    • Scottish adjuvant tamoxifen trial: a randomized study updated to 15years
    • Stewart H.J., Prescott R.J., Forrest A.P. Scottish adjuvant tamoxifen trial: a randomized study updated to 15years. J Natl Cancer Inst 2001, 93:456-462.
    • (2001) J Natl Cancer Inst , vol.93 , pp. 456-462
    • Stewart, H.J.1    Prescott, R.J.2    Forrest, A.P.3
  • 27
    • 0022468199 scopus 로고
    • Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast carcinoma
    • Sawka C.A., Pritchard K.I., Paterson A.H., et al. Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast carcinoma. Cancer Res 1986, 46:3152-3156.
    • (1986) Cancer Res , vol.46 , pp. 3152-3156
    • Sawka, C.A.1    Pritchard, K.I.2    Paterson, A.H.3
  • 28
    • 0032537396 scopus 로고    scopus 로고
    • Tamoxifen for early breast cancer: an overview of the randomised trials
    • Early Breast Cancer Trialists' Collaborative Group
    • Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998, 351:1451-1467. Early Breast Cancer Trialists' Collaborative Group.
    • (1998) Lancet , vol.351 , pp. 1451-1467
  • 29
    • 4944258278 scopus 로고    scopus 로고
    • Tamoxifen for early breast cancer (Cochrane Review)
    • Early Breast Cancer Trialists' Collaborative Group, The Cochrane Library, Chichester, UK
    • Tamoxifen for early breast cancer (Cochrane Review). The Cochrane Library 2004, 1-38. Early Breast Cancer Trialists' Collaborative Group, The Cochrane Library, Chichester, UK.
    • (2004) The Cochrane Library , pp. 1-38
  • 31
    • 0032537990 scopus 로고    scopus 로고
    • Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study
    • Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 1998, 90:1371-1388.
    • (1998) J Natl Cancer Inst , vol.90 , pp. 1371-1388
    • Fisher, B.1    Costantino, J.P.2    Wickerham, D.L.3
  • 32
    • 80052059849 scopus 로고    scopus 로고
    • First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial
    • Cuzick J., Forbes J., Edwards R., et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002, 360:817-824.
    • (2002) Lancet , vol.360 , pp. 817-824
    • Cuzick, J.1    Forbes, J.2    Edwards, R.3
  • 33
    • 33847793068 scopus 로고    scopus 로고
    • Long-term results of tamoxifen prophylaxis for breast cancer - 96-month follow-up of the randomized IBIS-I trial
    • Cuzick J., Forbes J.F., Sestak I., et al. Long-term results of tamoxifen prophylaxis for breast cancer - 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007, 99:272-282.
    • (2007) J Natl Cancer Inst , vol.99 , pp. 272-282
    • Cuzick, J.1    Forbes, J.F.2    Sestak, I.3
  • 34
    • 74849127916 scopus 로고    scopus 로고
    • Women's decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid
    • Fagerlin A., Zikmund-Fisher B.J., Nair V., et al. Women's decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid. Breast Cancer Res Treat 2010, 119:613-620.
    • (2010) Breast Cancer Res Treat , vol.119 , pp. 613-620
    • Fagerlin, A.1    Zikmund-Fisher, B.J.2    Nair, V.3
  • 35
    • 77952569256 scopus 로고    scopus 로고
    • Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer
    • Lewis J.D., Chagpar A.B., Shaughnessey E.A., Nurko J., McMasters K., Edwards M.J. Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer. Cancer 2010, 116:2307-2315.
    • (2010) Cancer , vol.116 , pp. 2307-2315
    • Lewis, J.D.1    Chagpar, A.B.2    Shaughnessey, E.A.3    Nurko, J.4    McMasters, K.5    Edwards, M.J.6
  • 36
    • 84877007293 scopus 로고    scopus 로고
    • Fareston summary of product characteristics. Available at <>[accessed 12.03.12
    • Fareston summary of product characteristics. Available at <>; 2010 [accessed 12.03.12. http://www.medicines.org.uk/emc/medicine/10221/SPC/Fareston+60mg+Tablets.
    • (2010)
  • 37
    • 10644283864 scopus 로고    scopus 로고
    • Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene
    • Martino S., Cauley J.A., Barrett-Connor E., et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004, 96:1751-1761.
    • (2004) J Natl Cancer Inst , vol.96 , pp. 1751-1761
    • Martino, S.1    Cauley, J.A.2    Barrett-Connor, E.3
  • 38
    • 0035687124 scopus 로고    scopus 로고
    • The MORE trial: multiple outcomes for raloxifen evaluation - breast cancer as a secondary end point: implications for prevention
    • Dickler M.N., Norton L. The MORE trial: multiple outcomes for raloxifen evaluation - breast cancer as a secondary end point: implications for prevention. Ann N Y Acad Sci 2001, 949:134-142.
    • (2001) Ann N Y Acad Sci , vol.949 , pp. 134-142
    • Dickler, M.N.1    Norton, L.2
  • 39
    • 33745249570 scopus 로고    scopus 로고
    • Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial
    • Vogel V.G., Constantino J.P., Wickerham D.L., et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA 2006, 295:2727-2741.
    • (2006) JAMA , vol.295 , pp. 2727-2741
    • Vogel, V.G.1    Constantino, J.P.2    Wickerham, D.L.3
  • 40
    • 84876979537 scopus 로고    scopus 로고
    • Evista prescribing information. Available at <> [accessed 12.03.12].
    • Evista prescribing information. Available at <>; 2010 [accessed 12.03.12]. http://www.pi.lilly.com/us/evista-pi.pdf.
    • (2010)
  • 41
    • 77953529620 scopus 로고    scopus 로고
    • Update of the national surgical adjuvant breast and bowel project study of tamoxifen and raloxifene (STAR) P-2 Trial: preventing breast cancer
    • Vogel V.G., Constantino J.P., Wickerham D.L., et al. Update of the national surgical adjuvant breast and bowel project study of tamoxifen and raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res (Phila) 2010, 3:696-706.
    • (2010) Cancer Prev Res (Phila) , vol.3 , pp. 696-706
    • Vogel, V.G.1    Constantino, J.P.2    Wickerham, D.L.3
  • 43
    • 38149063362 scopus 로고    scopus 로고
    • The role of ovarian ablation in the adjuvant therapy of breast cancer
    • Tan S.H., Wolff A.C. The role of ovarian ablation in the adjuvant therapy of breast cancer. Curr Oncol Rep 2008, 10:27-37.
    • (2008) Curr Oncol Rep , vol.10 , pp. 27-37
    • Tan, S.H.1    Wolff, A.C.2
  • 44
    • 34748918347 scopus 로고    scopus 로고
    • Controversies of adjuvant endocrine treatment for breast cancer and recommendations of the 2007 St Gallen conference
    • Rabaglio M., Aebi S., Castiglione-Gertsch M. Controversies of adjuvant endocrine treatment for breast cancer and recommendations of the 2007 St Gallen conference. Lancet Oncol 2007, 8:940-949.
    • (2007) Lancet Oncol , vol.8 , pp. 940-949
    • Rabaglio, M.1    Aebi, S.2    Castiglione-Gertsch, M.3
  • 45
    • 54749150299 scopus 로고    scopus 로고
    • Ovarian suppression in the management of premenopausal breast cancer: methods and efficacy in adjuvant and metastatic settings
    • McDonald Wade S., Hackney M.H., Khatcheressian J., Lyckholm L.J. Ovarian suppression in the management of premenopausal breast cancer: methods and efficacy in adjuvant and metastatic settings. Oncology 2008, 75:192-202.
    • (2008) Oncology , vol.75 , pp. 192-202
    • McDonald Wade, S.1    Hackney, M.H.2    Khatcheressian, J.3    Lyckholm, L.J.4
  • 46
    • 33745308514 scopus 로고    scopus 로고
    • Adjuvant goserelin in pre-menopausal patients with early breast cancer: results from the ZIPP study
    • Baum M., Hackshaw A., Houghton J., et al. Adjuvant goserelin in pre-menopausal patients with early breast cancer: results from the ZIPP study. Eur J Cancer 2006, 42:895-904.
    • (2006) Eur J Cancer , vol.42 , pp. 895-904
    • Baum, M.1    Hackshaw, A.2    Houghton, J.3
  • 47
    • 62349124975 scopus 로고    scopus 로고
    • Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer
    • Hackshaw A., Baum M., Fornander T., et al. Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer. J Natl Cancer Inst 2009, 101:341-349.
    • (2009) J Natl Cancer Inst , vol.101 , pp. 341-349
    • Hackshaw, A.1    Baum, M.2    Fornander, T.3
  • 48
    • 0037115422 scopus 로고    scopus 로고
    • Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study
    • Jonat W., Kaufmann M., Sauerbrei W., et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 2002, 20:4628-4635.
    • (2002) J Clin Oncol , vol.20 , pp. 4628-4635
    • Jonat, W.1    Kaufmann, M.2    Sauerbrei, W.3
  • 49
    • 0042848736 scopus 로고    scopus 로고
    • Survival analyses from the ZEBRA study: goserelin (Zoladex™) versus CMF in premenopausal women with node-positive breast cancer
    • Kaufmann M., Jonat W., Blamey R., et al. Survival analyses from the ZEBRA study: goserelin (Zoladex™) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer 2003, 39:1711-1717.
    • (2003) Eur J Cancer , vol.39 , pp. 1711-1717
    • Kaufmann, M.1    Jonat, W.2    Blamey, R.3
  • 50
    • 34248574344 scopus 로고    scopus 로고
    • Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials
    • Cuzick J., Ambroisine L., Davidson N., et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007, 369:1711-1723.
    • (2007) Lancet , vol.369 , pp. 1711-1723
    • Cuzick, J.1    Ambroisine, L.2    Davidson, N.3
  • 51
    • 80053151094 scopus 로고    scopus 로고
    • Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer
    • Karlsson P., Sun Z., Braun D., et al. Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer. Ann Oncol 2011, 22:2216-2226.
    • (2011) Ann Oncol , vol.22 , pp. 2216-2226
    • Karlsson, P.1    Sun, Z.2    Braun, D.3
  • 52
    • 50649113295 scopus 로고    scopus 로고
    • Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?
    • Miller W.R., Bartlett J., Brodie A.M., et al. Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?. Oncologist 2008, 13:829-837.
    • (2008) Oncologist , vol.13 , pp. 829-837
    • Miller, W.R.1    Bartlett, J.2    Brodie, A.M.3
  • 53
    • 0020326760 scopus 로고
    • Aminoglutethimide in the treatment of advanced postmenopausal breast cancer
    • Harris A.L., Powles T.J., Smith I.E. Aminoglutethimide in the treatment of advanced postmenopausal breast cancer. Cancer Res 1982, 42(8 Suppl):3405s-3408s.
    • (1982) Cancer Res , vol.42 , Issue.8 SUPPL.
    • Harris, A.L.1    Powles, T.J.2    Smith, I.E.3
  • 54
    • 8944237006 scopus 로고    scopus 로고
    • Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
    • Buzdar A., Jonat W., Howell A., et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol 1996, 14:2000-2011.
    • (1996) J Clin Oncol , vol.14 , pp. 2000-2011
    • Buzdar, A.1    Jonat, W.2    Howell, A.3
  • 55
    • 0032530988 scopus 로고    scopus 로고
    • Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group.
    • Buzdar A.U., Jonat W., Howell A., et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 1998, 83:1142-1152.
    • (1998) Cancer , vol.83 , pp. 1142-1152
    • Buzdar, A.U.1    Jonat, W.2    Howell, A.3
  • 56
    • 7344242595 scopus 로고    scopus 로고
    • Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5mg daily, 0.5mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3)
    • Gershanovich M., Chaudri H.A., Campos D., et al. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5mg daily, 0.5mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). Ann Oncol 1998, 9:639-645.
    • (1998) Ann Oncol , vol.9 , pp. 639-645
    • Gershanovich, M.1    Chaudri, H.A.2    Campos, D.3
  • 57
    • 0031943424 scopus 로고    scopus 로고
    • Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
    • Dombernowsky P., Smith I., Falkson G., et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998, 16:453-461.
    • (1998) J Clin Oncol , vol.16 , pp. 453-461
    • Dombernowsky, P.1    Smith, I.2    Falkson, G.3
  • 58
    • 0034669484 scopus 로고    scopus 로고
    • Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.
    • Nabholtz J.M., Buzdar A., Pollak M., et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000, 18:3758-3767.
    • (2000) J Clin Oncol , vol.18 , pp. 3758-3767
    • Nabholtz, J.M.1    Buzdar, A.2    Pollak, M.3
  • 59
    • 0034669435 scopus 로고    scopus 로고
    • Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study
    • Bonneterre J., Thürlimann B., Robertson J.F., et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J Clin Oncol 2000, 18:3748-3757.
    • (2000) J Clin Oncol , vol.18 , pp. 3748-3757
    • Bonneterre, J.1    Thürlimann, B.2    Robertson, J.F.3
  • 60
    • 0343584508 scopus 로고    scopus 로고
    • Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group
    • Mouridsen H., Gershanovich M., Sun Y., et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001, 19:2596-2606.
    • (2001) J Clin Oncol , vol.19 , pp. 2596-2606
    • Mouridsen, H.1    Gershanovich, M.2    Sun, Y.3
  • 61
    • 54449099359 scopus 로고    scopus 로고
    • Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group
    • Paridaens R.J., Dirix L.Y., Beex L.V., et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 2008, 26:4883-4890.
    • (2008) J Clin Oncol , vol.26 , pp. 4883-4890
    • Paridaens, R.J.1    Dirix, L.Y.2    Beex, L.V.3
  • 62
    • 33644550685 scopus 로고    scopus 로고
    • Changing the gold standard in adjuvant therapy for breast cancer: from tamoxifen to aromatase inhibition
    • Gltick S. Changing the gold standard in adjuvant therapy for breast cancer: from tamoxifen to aromatase inhibition. Biomed Pharmacother 2005, 59(Suppl 2):S321-S322.
    • (2005) Biomed Pharmacother , vol.59 , Issue.SUPPL. 2
    • Gltick, S.1
  • 63
    • 0037157603 scopus 로고    scopus 로고
    • Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
    • The ATAC Trialists' Group
    • Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002, 359:2131-2139. The ATAC Trialists' Group.
    • (2002) Lancet , vol.359 , pp. 2131-2139
  • 64
    • 11444251764 scopus 로고    scopus 로고
    • Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
    • ATAC Trialists' Group
    • Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005, 365:60-62. ATAC Trialists' Group.
    • (2005) Lancet , vol.365 , pp. 60-62
  • 65
    • 29544433211 scopus 로고    scopus 로고
    • A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer
    • The Breast International Group (BIG) 1-98 Collaborative Group
    • A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005, 353:2747-2757. The Breast International Group (BIG) 1-98 Collaborative Group.
    • (2005) N Engl J Med , vol.353 , pp. 2747-2757
  • 66
    • 10744223655 scopus 로고    scopus 로고
    • A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer
    • Coombes R.C., Hall E., Gibson L.J., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004, 350:1081-1092.
    • (2004) N Engl J Med , vol.350 , pp. 1081-1092
    • Coombes, R.C.1    Hall, E.2    Gibson, L.J.3
  • 67
    • 78649603622 scopus 로고    scopus 로고
    • Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial
    • Cuzick J., Sestak I., Baum M., et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010, 11:1135-1141.
    • (2010) Lancet Oncol , vol.11 , pp. 1135-1141
    • Cuzick, J.1    Sestak, I.2    Baum, M.3
  • 68
    • 69049113989 scopus 로고    scopus 로고
    • Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer
    • The BIG 1-98 Collaborative International Breast Cancer Study Group
    • Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009, 361:766-776. The BIG 1-98 Collaborative International Breast Cancer Study Group.
    • (2009) N Engl J Med , vol.361 , pp. 766-776
  • 69
    • 79952748821 scopus 로고    scopus 로고
    • Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study
    • Colleoni M., Giobbie-Hurder A., Regan M., et al. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol 2011, 29:1117-1124.
    • (2011) J Clin Oncol , vol.29 , pp. 1117-1124
    • Colleoni, M.1    Giobbie-Hurder, A.2    Regan, M.3
  • 70
    • 75749092296 scopus 로고    scopus 로고
    • Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen
    • Dowsett M., Cuzick J., Ingle J., et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010, 28:509-518.
    • (2010) J Clin Oncol , vol.28 , pp. 509-518
    • Dowsett, M.1    Cuzick, J.2    Ingle, J.3
  • 71
    • 33745613829 scopus 로고    scopus 로고
    • Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial
    • Boccardo F., Rubagotti A., Guglielmini P., et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol 2006, 17(Suppl 7):vii10-vii14.
    • (2006) Ann Oncol , vol.17 , Issue.SUPPL. 7 , pp. 710-714
    • Boccardo, F.1    Rubagotti, A.2    Guglielmini, P.3
  • 72
    • 23444446523 scopus 로고    scopus 로고
    • Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial
    • Jakesz R., Jonat W., Gnant M., et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005, 366:455-462.
    • (2005) Lancet , vol.366 , pp. 455-462
    • Jakesz, R.1    Jonat, W.2    Gnant, M.3
  • 73
    • 34447574894 scopus 로고    scopus 로고
    • Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after 2years of treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study
    • Kaufmann M., Jonat W., Hilfrich J., et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after 2years of treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol 2007, 25:2664-2670.
    • (2007) J Clin Oncol , vol.25 , pp. 2664-2670
    • Kaufmann, M.1    Jonat, W.2    Hilfrich, J.3
  • 74
    • 33751321384 scopus 로고    scopus 로고
    • Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis
    • Jonat W., Gnant M., Boccardo F., et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol 2006, 7:991-996.
    • (2006) Lancet Oncol , vol.7 , pp. 991-996
    • Jonat, W.1    Gnant, M.2    Boccardo, F.3
  • 75
    • 14544281511 scopus 로고    scopus 로고
    • BIG 1-98: A prospective randomized double-blind double-dummy phase III study to evaluate letrozole as adjuvant endocrine therapy for postmenopausal women with receptor- positive breast cancer
    • BIG 1-98 Collaborative Group
    • BIG 1-98: A prospective randomized double-blind double-dummy phase III study to evaluate letrozole as adjuvant endocrine therapy for postmenopausal women with receptor- positive breast cancer. The Breast 2005, 14(Suppl 1):S3. BIG 1-98 Collaborative Group.
    • (2005) The Breast , vol.14 , Issue.SUPPL. 1
  • 76
    • 19344364880 scopus 로고    scopus 로고
    • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
    • Early Breast Cancer Trialists' Collaborative Group
    • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717. Early Breast Cancer Trialists' Collaborative Group.
    • (2005) Lancet , vol.365 , pp. 1687-1717
  • 77
    • 24744450378 scopus 로고    scopus 로고
    • Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17
    • Goss P.E., Ingle J.N., Martino S., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005, 97:1262-1271.
    • (2005) J Natl Cancer Inst , vol.97 , pp. 1262-1271
    • Goss, P.E.1    Ingle, J.N.2    Martino, S.3
  • 78
    • 38449107897 scopus 로고    scopus 로고
    • Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian breast cancer and colorectal cancer study group trial 6a
    • Jakesz R., Greil R., Gnant M., et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian breast cancer and colorectal cancer study group trial 6a. J Natl Cancer Inst 2007, 99:1845-1853.
    • (2007) J Natl Cancer Inst , vol.99 , pp. 1845-1853
    • Jakesz, R.1    Greil, R.2    Gnant, M.3
  • 79
    • 42949104549 scopus 로고    scopus 로고
    • Benefit From exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat.analysis of the national surgical adjuvant breast and bowel project B-33 trial
    • Mamounas E.P., Jeong J.H., Wickerham D.L., et al. Benefit From exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat.analysis of the national surgical adjuvant breast and bowel project B-33 trial. J Clin Oncol 2008, 26:1965-1971.
    • (2008) J Clin Oncol , vol.26 , pp. 1965-1971
    • Mamounas, E.P.1    Jeong, J.H.2    Wickerham, D.L.3
  • 80
    • 0026395885 scopus 로고
    • A potent specific pure antiestrogen with clinical potential
    • Wakeling A.E., Dukes M., Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res 1991, 51:3867-3873.
    • (1991) Cancer Res , vol.51 , pp. 3867-3873
    • Wakeling, A.E.1    Dukes, M.2    Bowler, J.3
  • 81
    • 0037102121 scopus 로고    scopus 로고
    • Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment
    • Howell A., Robertson J.F.R., Quaresma J. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002, 20:3396-3403.
    • (2002) J Clin Oncol , vol.20 , pp. 3396-3403
    • Howell, A.1    Robertson, J.F.R.2    Quaresma, J.3
  • 83
    • 65649119341 scopus 로고    scopus 로고
    • A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health
    • Ewer M.S., Glück S. A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health. Cancer 2009, 115:1813-1826.
    • (2009) Cancer , vol.115 , pp. 1813-1826
    • Ewer, M.S.1    Glück, S.2
  • 84
    • 79951710902 scopus 로고    scopus 로고
    • Clinical review: effect of endocrine therapies on bone in breast cancer patients
    • Santen R.J. Clinical review: effect of endocrine therapies on bone in breast cancer patients. J Clin Endocrinol Metab 2011, 96:308-319.
    • (2011) J Clin Endocrinol Metab , vol.96 , pp. 308-319
    • Santen, R.J.1
  • 85
    • 0037102126 scopus 로고    scopus 로고
    • Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial
    • Osborne C.K., Pippen J., Jones S.E., et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002, 20:3386-3395.
    • (2002) J Clin Oncol , vol.20 , pp. 3386-3395
    • Osborne, C.K.1    Pippen, J.2    Jones, S.E.3
  • 86
    • 0038683988 scopus 로고    scopus 로고
    • Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials
    • Robertson J.F., Osborne C.K., Howell A., et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003, 98:229-238.
    • (2003) Cancer , vol.98 , pp. 229-238
    • Robertson, J.F.1    Osborne, C.K.2    Howell, A.3
  • 87
    • 2442648038 scopus 로고    scopus 로고
    • Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial
    • Howell A., Robertson J.F.R., Abram P., et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004, 22:1605-1613.
    • (2004) J Clin Oncol , vol.22 , pp. 1605-1613
    • Howell, A.1    Robertson, J.F.R.2    Abram, P.3
  • 88
    • 0028084758 scopus 로고
    • Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer
    • DeFriend D.J., Howell A., Nicholson R.I., et al. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res 1994, 54:408-414.
    • (1994) Cancer Res , vol.54 , pp. 408-414
    • DeFriend, D.J.1    Howell, A.2    Nicholson, R.I.3
  • 89
    • 0035884408 scopus 로고    scopus 로고
    • Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer
    • Robertson J.F., Nicholson R.I., Bundred N.J., et al. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 2001, 61:6739-6746.
    • (2001) Cancer Res , vol.61 , pp. 6739-6746
    • Robertson, J.F.1    Nicholson, R.I.2    Bundred, N.J.3
  • 90
    • 78049523306 scopus 로고    scopus 로고
    • Results of the CONFIRM Phase III trial comparing fulvestrant 250mg with fulvestrant 500mg in postmenopausal women with estrogen receptor-positive advanced breast cancer
    • Di Leo A., Jerusalem G., Petruzelka L., et al. Results of the CONFIRM Phase III trial comparing fulvestrant 250mg with fulvestrant 500mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010, 28:4594-4600.
    • (2010) J Clin Oncol , vol.28 , pp. 4594-4600
    • Di Leo, A.1    Jerusalem, G.2    Petruzelka, L.3
  • 91
    • 29244440841 scopus 로고    scopus 로고
    • Clinical trial update: international breast cancer study group
    • Price K.N., Goldhirsch A. Clinical trial update: international breast cancer study group. Breast Cancer Res 2005, 7:252-254.
    • (2005) Breast Cancer Res , vol.7 , pp. 252-254
    • Price, K.N.1    Goldhirsch, A.2
  • 92
    • 60549097419 scopus 로고    scopus 로고
    • Endocrine therapy plus zoledronic acid in premenopausal breast cancer
    • Gnant M., Mlineritsch B., Schippinger W., et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009, 360:679-691.
    • (2009) N Engl J Med , vol.360 , pp. 679-691
    • Gnant, M.1    Mlineritsch, B.2    Schippinger, W.3
  • 93
    • 84866654068 scopus 로고    scopus 로고
    • ER and PI3K independently modulate endocrine resistance in ER positive breast cancer
    • Van Tine B.A., Crowder R.J., Ellis M.J. ER and PI3K independently modulate endocrine resistance in ER positive breast cancer. Cancer Discov 2011, 1:287-288.
    • (2011) Cancer Discov , vol.1 , pp. 287-288
    • Van Tine, B.A.1    Crowder, R.J.2    Ellis, M.J.3
  • 94
    • 84855364818 scopus 로고    scopus 로고
    • Global characterization of the SRC-1 transcriptome identifies ADAM22 as an ER-independent mediator of endocrine resistant breast cancer
    • McCartan D., Bolger J., Fagan A., et al. Global characterization of the SRC-1 transcriptome identifies ADAM22 as an ER-independent mediator of endocrine resistant breast cancer. Cancer Res 2012, 72:220-229.
    • (2012) Cancer Res , vol.72 , pp. 220-229
    • McCartan, D.1    Bolger, J.2    Fagan, A.3
  • 95
    • 80054874720 scopus 로고    scopus 로고
    • Biological mechanisms and clinical implications of endocrine resistance in breast cancer
    • Giuliano M., Schifp R., Osborne C.K., Trivedi M.V. Biological mechanisms and clinical implications of endocrine resistance in breast cancer. Breast 2011, 20(Suppl 3):S42-S49.
    • (2011) Breast , vol.20 , Issue.SUPPL. 3
    • Giuliano, M.1    Schifp, R.2    Osborne, C.K.3    Trivedi, M.V.4
  • 96
    • 84876996359 scopus 로고    scopus 로고
    • TAMRAD: A GINECO randomized Phase II Trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to aromatase inhibitors (AI). Abstract presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, USA, 8-12 December (Abstract S1-6).
    • Bachelot T, Bourgier C, Cropet C, et al. TAMRAD: A GINECO randomized Phase II Trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to aromatase inhibitors (AI). Abstract presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, USA, 8-12 December, 2010 (Abstract S1-6).
    • (2010)
    • Bachelot, T.1    Bourgier, C.2    Cropet, C.3
  • 97
    • 84863078767 scopus 로고    scopus 로고
    • Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer
    • Baselga J., Campone M., Piccart M., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012, 366:520-529.
    • (2012) N Engl J Med , vol.366 , pp. 520-529
    • Baselga, J.1    Campone, M.2    Piccart, M.3
  • 98
    • 79551576468 scopus 로고    scopus 로고
    • Mechanisms of endocrine resistance in breast cancer
    • Osborne C.K., Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 2011, 62:233-247.
    • (2011) Annu Rev Med , vol.62 , pp. 233-247
    • Osborne, C.K.1    Schiff, R.2
  • 99
    • 12144269500 scopus 로고    scopus 로고
    • Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer
    • Osborne C.K., Shou J., Massarweh S., Schiff R. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 2005, 11:865s-870s.
    • (2005) Clin Cancer Res , vol.11
    • Osborne, C.K.1    Shou, J.2    Massarweh, S.3    Schiff, R.4
  • 100
    • 80053341141 scopus 로고    scopus 로고
    • Simultaneous inhibition of estrogen receptor and the HER2 pathway in breast cancer: effects of HER2 abundance
    • Emde A., Mahlknecht G., Maslak K., et al. Simultaneous inhibition of estrogen receptor and the HER2 pathway in breast cancer: effects of HER2 abundance. Transl Oncol 2011, 4:293-300.
    • (2011) Transl Oncol , vol.4 , pp. 293-300
    • Emde, A.1    Mahlknecht, G.2    Maslak, K.3
  • 101
    • 82155187061 scopus 로고    scopus 로고
    • Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers - role of estrogen receptor and HER2 reactivation
    • Wang Y.C., Morrison G., Gillihan R., et al. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers - role of estrogen receptor and HER2 reactivation. Breast Cancer Res 2011, 13:R121.
    • (2011) Breast Cancer Res , vol.13
    • Wang, Y.C.1    Morrison, G.2    Gillihan, R.3
  • 102
    • 77649100030 scopus 로고    scopus 로고
    • Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer
    • Schwartzberg L.S., Franco S.X., Florance A., O'Rourke L., Maltzman J., Johnston S. Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. Oncologist 2010, 15:122-129.
    • (2010) Oncologist , vol.15 , pp. 122-129
    • Schwartzberg, L.S.1    Franco, S.X.2    Florance, A.3    O'Rourke, L.4    Maltzman, J.5    Johnston, S.6
  • 104
    • 37249069903 scopus 로고    scopus 로고
    • Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response
    • Bayliss J., Hilger A., Vishnu P., Diehl K., El-Ashry D. Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response. Clin Cancer Res 2007, 13:7029-7036.
    • (2007) Clin Cancer Res , vol.13 , pp. 7029-7036
    • Bayliss, J.1    Hilger, A.2    Vishnu, P.3    Diehl, K.4    El-Ashry, D.5
  • 105
    • 80355135172 scopus 로고    scopus 로고
    • Cancer epigenetics: a perspective on the role of DNA methylation in acquired endocrine resistance
    • Trimarchi M.P., Mouangsavanh M., Huang T.H. Cancer epigenetics: a perspective on the role of DNA methylation in acquired endocrine resistance. Chin J Cancer 2011, 30:749-756.
    • (2011) Chin J Cancer , vol.30 , pp. 749-756
    • Trimarchi, M.P.1    Mouangsavanh, M.2    Huang, T.H.3
  • 106
    • 75149159605 scopus 로고    scopus 로고
    • Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors
    • Wang L., Ellsworth K.A., Moon I., et al. Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. Cancer Res 2010, 70:319-328.
    • (2010) Cancer Res , vol.70 , pp. 319-328
    • Wang, L.1    Ellsworth, K.A.2    Moon, I.3
  • 107
    • 84876996269 scopus 로고    scopus 로고
    • Cancer Research UK. Statistics and outlook for breast cancer. Available at <> [accessed 12.03.12].
    • Cancer Research UK. Statistics and outlook for breast cancer. Available at <>; 2011 [accessed 12.03.12]. http://www.cancerhelp.cancerresearchuk.org/type/breast-cancer/treatment/statistics-and-outlook-for-breast-cancer.
    • (2011)


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.